Serogroup A meningococcal conjugate (PsA-TT) vaccine coverage and measles vaccine coverage in Burkina Faso--implications for introduction of PsA-TT into the Expanded Programme on Immunization

Vaccine. 2015 Mar 17;33(12):1492-8. doi: 10.1016/j.vaccine.2015.01.043. Epub 2015 Jan 28.

Abstract

Background: A new serogroup A meningococcal conjugate vaccine (PsA-TT, MenAfriVac™) has been developed to combat devastating serogroup A Neisseria meningitis (MenA) epidemics in Africa. A mass immunization campaign targeting 1-29 year olds was conducted in Burkina Faso in December 2010. Protection of subsequent infant cohorts will be necessary through either introduction of PsA-TT into the routine Expanded Programme on Immunization (EPI) or periodic repeat mass vaccination campaigns.

Objectives: To inform future immunization policy for PsA-TT vaccination of infants through a comparison of PsA-TT campaign vaccination coverage and routine measles-containing vaccine (MCV) coverage in Burkina Faso.

Methods: A national survey was conducted in Burkina Faso during December 17-27, 2011 using stratified cluster sampling to assess PsA-TT vaccine coverage achieved by the 2010 nationwide immunization campaign among 2-30 year olds and routine MCV coverage among 12-23 month olds. Coverage estimates and 95% Confidence Intervals (CI) were calculated, reasons for non-vaccination and methods of campaign communication were described, and a multivariable analysis for factors associated with vaccination was conducted.

Results: National overall PsA-TT campaign coverage was 95.9% (95% CI: 95.0-96.7) with coverage greater than 90% all 13 regions of Burkina Faso. National overall routine MCV coverage was 92.5% (95% CI: 90.5-94.1), but ranged from 75.3% to 95.3% by region. The primary predictor for PsA-TT vaccination among all age groups was a head of household informed of the campaign. PsA-TT vaccination was more likely in residents of rural settings, whereas MCV vaccination was more likely in residents of urban settings.

Conclusion: Overall national vaccination rates in Burkina Faso were similar for PsA-TT and MCV vaccine. The regions with MCV coverage below targets may be at risk for sub-optimal vaccination coverage if PsA-TT is introduced in EPI. These results highlight the need for assessments of routine vaccination coverage to guide PsA-TT immunization policy in meningitis belt countries.

Keywords: Burkina Faso; Conjugate meningococcal vaccine; Measles; Measles vaccine; PsA-TT; Serogroup A meningococcal meningitis.

MeSH terms

  • Adolescent
  • Adult
  • Africa
  • Burkina Faso / epidemiology
  • Child
  • Child, Preschool
  • Health Care Surveys / statistics & numerical data
  • Health Policy
  • Humans
  • Immunization Programs / legislation & jurisprudence
  • Immunization Programs / statistics & numerical data*
  • Infant
  • Male
  • Measles Vaccine / administration & dosage*
  • Meningitis, Meningococcal / prevention & control
  • Meningococcal Vaccines / administration & dosage*
  • Neisseria meningitidis, Serogroup A / immunology*
  • Public Health Surveillance
  • Rural Health Services*
  • Vaccines, Conjugate / administration & dosage
  • Young Adult

Substances

  • Measles Vaccine
  • MenAfriVac
  • Meningococcal Vaccines
  • Vaccines, Conjugate